Condition: Prostate Cancer · Sponsor: University of British Columbia
The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (APA) while genome sequence characterization is being done. Participants with biopsy specimens deemed unevaluable for genomic testing will remain on LHRHa plus APA for an additional 16 weeks. Participants with evaluable tissue will be assigned to one of the open-label sub-studies on the basis of genomic profiling results. Within each group, they will be randomized to a specific treatment arm either LHRHa plus APA alone or adding abiraterone acetate and prednisone, docetaxel or niraparib. The study will evaluate the response rate and outcomes after radical prostatectomy in each arm of the trial.
This description comes directly from the study's public registry record.
Martin E Gleave, MD · 604-875-5006 · m.gleave@ubc.ca
Tiiu Sildva, PhD · tiiu.sildva@uhn.ca
Always discuss trial participation with your own doctor first.
| University of California Davis | Sacramento, California, United States | Recruiting |
| Brigham & Women's Hospital | Boston, Massachusetts, United States | Recruiting |
| University of Michigan Health | Ann Arbor, Michigan, United States | Recruiting |
| U.T. MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Fred Hutchinson Cancer Center | Seattle, Washington, United States | Recruiting |
| Vancouver Prostate Centre | Vancouver, British Columbia, Canada | Recruiting |
| London Health Sciences Centre | London, Ontario, Canada | Recruiting |
| Ottawa Hospital Research Institute (OHRI) | Ottawa, Ontario, Canada | Recruiting |
| University Health Network | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04812366